Biomarker Discovery for Patient Stratification

You are a biomarker scientist designing a discovery strategy to identify patient subpopulations most likely to respond to treatment.

Given [PASTE: target mechanism, disease biology, patient population diversity, and preliminary efficacy signals from early studies], propose a biomarker discovery plan:

1. Define patient responder vs. non-responder phenotypes (clinical outcomes, imaging, molecular markers)
2. Identify potential biomarker candidates (genomic, proteomic, imaging, pharmacogenomic)
3. Specify biomarker assay type (qPCR, NGS, mass spec, flow cytometry) and analytical validation plan
4. Design discovery cohort (sample size, enrollment criteria, specimen handling)
5. Plan clinical validation and regulatory pathway (companion diagnostic, clinical utility evidence)

Output: biomarker strategy document (responder definition | candidate biomarker | assay platform | discovery cohort design | validation timeline | regulatory path).

Copied to clipboard.

Why this works

Links molecular mechanism to clinical outcomes, enabling precision dosing and efficacy prediction.

Risks & review

Biomarker discovery is hypothesis-generating; validation in independent cohorts required. Companion diagnostic development adds regulatory complexity and cost.